Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis Collection

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05198661

Acronym

SNP

Enrollment

3500

Registered

2022-01-20

Start date

2022-08-02

Completion date

2032-08-02

Last updated

2024-02-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paraneoplastic Neurological Syndromes or Autoimmune Encephalitis

Keywords

Paraneoplastic Neurological Syndromes, Autoimmune Encephalitis, biological collection

Brief summary

Numerous neurological disorders affecting the central and peripheral nervous system can be attributed to the immune system through multiple effector mechanisms. However, current treatments could be drastically improved by faster and more accurate diagnosis. The sample collection will benefit to patients with rare neuroimmune syndromes such as Autoimmune Encephalitis (AE) and Paraneoplastic Neurological Syndromes (PNS) leading to a better and early diagnosis, as well as treatment improvement.

Interventions

BIOLOGICALCollection of biological sample with sera, CSF, buffy coat, PBMC, plasma.

Blood is collected only one time by blood sample to obtain serum, buffy coat, plasma and PBMC. 2 \*4ml of blood on dry tube 2 \*4ml of blood on EDTA tube If possibility of delivery in 48 hours at the Centre of Biological Resources, 7\*4ml of blood on heparin tube If cerebrospinal fluid has been drawn for diagnosis, remaining sample available will be stored in the collection

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Intervention model description

Blood sample

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patient with consent * Patient with well-characterized antibodies in serum or cerebrospinal fluid or not * Patient with neurological disorder compatible with PNS or auto-immune encephalitis

Exclusion criteria

* Refusal of consent * Patient under guardianship

Design outcomes

Primary

Measure	Time frame	Description
Blood Samples	10 years	Assessment of biocollection of blood samples
Cerebrospinal fluid biocollection	10 years	Assessment of biocollection of Cerebrospinal fluid

Secondary

Measure	Time frame	Description
Scientific collaboration	10 years	Number of project issued from the biocollection
Scientific	10 years	Number of scientific papers issued from the biocollection

Countries

France

Contacts

Primary ContactJerome HONNORAT, Pr

jerome.honnorat@chu-lyon.fr4 72 35 78 06

Backup ContactGeraldine PICARD

geraldine.picard@chu-lyon.fr4 72 35 58 42

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026